XIENCE Safety Differentiators

XIENCE Stent Design: Low Stent Thrombosis Rates

A universal aim in the industry is to minimize the incidence of stent thrombosis (ST). XIENCE can point to extremely low stent thrombosis rates, even among complex patient populations.

The XIENCE coating technology is a key factor in minimizing stent thrombosis.


Protecting Patients from Stent Thrombosis

XIENCE VS OTHER DRUG-ELUTING STENTS

At rates of 0.0% and 0.1%, XIENCE outperforms other drug-eluting stents (DES) for 30-day stent thrombosis  rates in these studies:

  • The Resolute All Comers trial was designed to be representative of everyday clinical practice.7
  • The Platinum Plus trial examined the XIENCE and Promus Element stents.8

 

Protecting Complex Patients

XIENCE VS BARE METAL STENTS

Compared to bare metal stents (BMS) in a meta-analysis of all-comer complex patients, XIENCE was shown to save lives. 

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.


SIGN UP
Sign up

† Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.


‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

  1. Kaul U. TUXEDO Trial 2-year data. TCT 2016.  
  2. Teeuwen K, et al. PRISON IV Trial. JACC Cardiovasc Interv. 2016. doi: 10.1016/ j.jcin.2016.10.017.
  3. Stone GW, et al. EXCEL Trial. N Engl J Med. 2016;375:2223-2235. doi: 10.1056/NEJMoa1610227.
  4. Lam M. TWENTE Trial. Am Heart J.  2015;169:69-77. doi: 10.1016/j.ahj.2014.10.011.  
  5. Sabaté M. EXAMINATION Trial 5-year data. ESC 2015.
  6. de Belder A, et al. XIMA Trial. JACC. 2014;63:1371–1375. 
  7. Serruys PW, et al. Resolute All Comers Trial. N Engl J Med. 2010;363:136-146. doi: 10.1056/NEJMoa1004130.
  8. Fajadet J. Platinum Plus. TCT 2012.
  9. Valgimigli M. Meta-analysis. EuroPCR 2014. 

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Are you a healthcare professional in the
U.S. or outside of the U.S.?